Menu
← Oncology Approval Tracker
FDA DECISION ·
Jaypirca
pirtobrutinib · Eli Lilly and Company
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory CLL or SLL previously treated with a covalent BTK inhibitor.
LAMPGEN ANALYSIS
Why it matters
Traditional approval also broadened the population from the 2023 accelerated label, which required prior BTK and BCL-2 inhibitor treatment.
What research teams should watch
Distinguish prior covalent and noncovalent BTK inhibitor exposure in screening and identify the specific reason prior therapy stopped.
PRIMARY RECORDS